---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-104434"
form_type: "8-K"
ticker: "ALUR"
cik: "0001964979"
company_name: "ALLURION TECHNOLOGIES, INC."
filed_at: "2026-03-12T23:59:59+00:00"
generated_at: "2026-05-15T13:56:20.768350+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Allurion appeals NYSE delisting; trading moves to OTC; FDA approval of balloon catalyst for relisting plan

## Summary
- NYSE notified Allurion on March 6, 2026 of delisting for failing to maintain $15M average global market cap over 30 consecutive days.
- Trading suspended after March 6, 2026; common stock and warrants now trade on OTCID Market under ALUR and ALUR.WS.
- Company appealed delisting determination and will attempt to regain compliance with NYSE or list on NYSE American.
- FDA approval of Allurion Gastric Balloon System (Feb 20, 2026) catalyzed plan to strengthen balance sheet and fund U.S. commercialization.
- CEO Dr. Shantanu Gaur expressed confidence in executing the plan to treat obesity in over 100M Americans.

## SEC filing metadata
- accession: 0001193125-26-104434
- form_type: 8-K
- ticker: ALUR
- cik: 0001964979
- company_name: ALLURION TECHNOLOGIES, INC.
- filed_at: 2026-03-12T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 3.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1964979/000119312526104434/0001193125-26-104434-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1964979/000119312526104434/alur-20260306.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-104434
- JSON: https://secwatch.observer/filing/0001193125-26-104434.json
- Plain text: https://secwatch.observer/filing/0001193125-26-104434.txt

## Source-grounded claims
- claim_id: 7407aeaa0ad4f12431c7bc9026028febaf2d56ee
  claim: ALLURION TECHNOLOGIES, INC. received a nyse delisting notice notice regarding market value (rules 802.01B).
  evidence_excerpt: March 6, 2026, the New York Stock Exchange (“NYSE”) notified Allurion Technologies, Inc. (“Allurion” or the “Company”) that it has determined to commence proceedings to delist the Company’s common stock, par value $0.0001 per share (the “Common Stock”), and warrants to purchase 0.056818 shares of Common Stock, with an exercise price of $202.50 per share of Common Stock (the “Warrants”), as a result of the Company’s non-compliance with Rule 802.01B of the NYSE Listed Company Manual that requires listing companies to maintain an average global market capitalization of at least $15 million over a
  evidence_url: https://www.sec.gov/Archives/edgar/data/1964979/000119312526104434/0001193125-26-104434-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.